Expansion of sales of “onti,” a medical exposure dose management system
First written in FY2019-Q3. 2 of 6 entries say "Advanced", first in FY2019. Latest entry: FY2022.
0 other companies' latest entry also says "Dropped".
- FY2022DroppedAnnual report
「The sales agency agreement with RYUKYU ISG Co., Ltd. was terminated in February 2022.」
The filing states that the onti sales agency agreement was terminated in February 2022, and does not continue the previous sales expansion policy. - FY2021AdvancedAnnual report
「The “onti” product, a radiation dose management system whose demand has risen following the Medical Care Act amendment this April and which supports the nuclear medicine examination department, is covered by the company's exclusive sales rights. It has received high industry ratings, and sales are expected as the company currently expands its marketing efforts.」
The company has explicitly stated that it acquired exclusive sales rights for onti and is currently expanding sales, with revenue recognition expected against the backdrop of the Medical Care Act amendment. - FY2020-Q2RestatedAnnual report
「Demand for the “onti” radiation dose management system has been rising rapidly in anticipation of the Medical Care Act amendment scheduled for April this year. It is the only system with functions specifically for the nuclear medicine examination field, has received high market ratings, and is expected to see further demand growth.」
The company continues to describe rising demand for onti against the backdrop of the Medical Care Act amendment, its functions in the nuclear medicine examination field, its high market ratings, and expected future demand growth. - FY2020-Q1RestatedAnnual report
「Demand for the “onti” radiation dose management system has been rising rapidly in anticipation of the Medical Care Act amendment scheduled for April this year. It is the only system with functions specifically for the nuclear medicine examination field and has received high market ratings.」
The company continues to describe rising demand for onti against the backdrop of the Medical Care Act amendment and its high market ratings, but does not specifically state that orders or sales were recorded during the current quarter. - FY2019AdvancedAnnual report
「Demand for the “onti” radiation dose management system has been rising rapidly in anticipation of the Medical Care Act amendment scheduled for April next year. It is the only system with functions specifically for the nuclear medicine examination field, has received high market ratings, and has led to orders from national research and development agencies and other organizations.」
The description of onti has progressed from market recognition in connection with the Medical Care Act amendment to orders from national research and development agencies and other organizations. - FY2019-Q3First statedAnnual report
「The “onti” radiation dose management system for nuclear medicine examinations, the only such system in Japan in anticipation of the Medical Care Act amendment scheduled for April next year, has received high industry ratings and is currently being marketed more aggressively, with sales expected from the next fiscal year.」
For the “onti” radiation dose management system for nuclear medicine examinations, the company has for the first time stated that it has received high industry ratings, expects sales from the next fiscal year, and is currently expanding sales ahead of the Medical Care Act amendment.